Abstract
Cold atmospheric plasma (CAP) has been found effective in tumor treatment and promises to be adjuvant agents for various tumors. In melanoma, it has been reported that CAP can alter metabolism, senescence, migration, apoptosis and autophagy, and improve efficacy of chemotherapeutic agents. Current first-line therapeutic agents of advanced melanoma are immune checkpoint blockade and BRAF inhibitor (BRAFi)/MEK inhibitor (MEKi). These agents have definite effects with fatal limitation, drug resistance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
